Deutsche Bank Aktiengesellschaft started coverage on shares of Bristol-Myers Squibb (NYSE:BMY – Free Report) in a report issued on Thursday, Marketbeat reports. The firm issued a hold rating and a $55.00 price objective on the biopharmaceutical company’s stock. Several other research firms also recently commented on BMY. William Blair downgraded shares of Bristol-Myers Squibb from […]
Highland Capital Management LLC lowered its stake in shares of Bristol-Myers Squibb (NYSE:BMY – Free Report) by 1.5% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 77,831 shares of the biopharmaceutical company’s stock after selling 1,155 shares during the period. Highland […]
Center for Financial Planning Inc. decreased its holdings in shares of Bristol-Myers Squibb (NYSE:BMY – Free Report) by 20.1% during the second quarter, HoldingsChannel reports. The institutional investor owned 1,190 shares of the biopharmaceutical company’s stock after selling 300 shares during the period. Center for Financial Planning Inc.’s holdings in Bristol-Myers Squibb were worth $76,000 […]
Kingswood Wealth Advisors LLC purchased a new position in Bristol-Myers Squibb (NYSE:BMY – Free Report) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 40,204 shares of the biopharmaceutical company’s stock, valued at approximately $2,571,000. Bristol-Myers Squibb accounts for 0.8% of Kingswood Wealth Advisors […]
Banque Cantonale Vaudoise lifted its holdings in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 9.3% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 126,479 shares of the biopharmaceutical company’s stock after buying an additional 10,784 shares during the quarter. Banque Cantonale Vaudoise’s holdings in […]